Aleksandra Wieczorek

7PUBLICATIONS
27CO-AUTHORS
Radiation therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 13, 2025
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Holger N Lode, Przemysław Holko, Aleksandra Wieczorek

|Jun 03, 2025
Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma.

Aleksandra Wieczorek, Katarzyna Śladowska, Holger N Lode

|Mar 13, 2024
Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma.

Agata Marjańska, Katarzyna Pawińska-Wąsikowska, Aleksandra Wieczorek

|Feb 24, 2024
Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.

Urszula Żebrowska, Walentyna Balwierz, Jarosław Wechowski

|Aug 26, 2023
Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data.

Aleksandra Wieczorek, Urszula Żebrowska, Marek Ussowicz

|Jul 14, 2023
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.

Holger N Lode, Ruth Ladenstein, Sascha Troschke-Meurer

Pageof 2

Frequent Collaborators

3 joint publications

Holger N Lode

2 joint publications

Sascha Troschke-Meurer

2 joint publications

Nikolai Siebert

2 joint publications

Katarzyna Pawińska-Wąsikowska